Literature DB >> 4055061

Respiratory superinfections after the use of third-generation cephem antibiotics.

A Saito, K Mori, Y Shigeno, K Yamaguchi, K Hara.   

Abstract

This paper is a report on our studies on superinfections in respiratory tract infections treated during the years 1981-1984. The isolated strains of Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus faecalis, Streptococcus faecium and glucose non-fermentative gram-negative rods such as Pseudomonas aeruginosa were resistant to third-generation cephem antibiotics. These organisms proved to be widely distributed in hospitals and were frequently isolated from the sputum, excised lung and cardiac blood. The colonization of the sputum by bacteria in respiratory tract infections before, during and after treatment with third-generation cephem antibiotics revealed a tendency for these organisms to appear after treatment. Among the gram-positive cocci, S. faecium was most resistant to these antibiotics, followed by S. faecalis, S. epidermidis and S. aureus in that order. The incidence of resistant isolates in 1984 exceeded that in 1983, suggesting an annual increase in resistant bacteria.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4055061     DOI: 10.1007/BF01644226

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  13 in total

1.  Cefotaxime in the treatment of pneumococcal pneumonia.

Authors:  S G Jenkinson; M S Briggs; R D Bryn
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

2.  Cefotaxime in the treatment of lower respiratory tract infections.

Authors:  P Hänninen; A Toivanen; O Vainio; P Toivanen
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

3.  Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic.

Authors:  V L Yu
Journal:  Ann Intern Med       Date:  1981-06       Impact factor: 25.391

4.  In vitro antibacterial activity of cefpiramide.

Authors:  M A Pfaller; A C Niles; P R Murray
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

5.  Pulmonary infection due to anaerobes in a hospital autopsy survey.

Authors:  A Saito; K Hara; K Yamaguchi; T Usui
Journal:  Rev Infect Dis       Date:  1984 Mar-Apr

6.  Clinical efficacy of cefotaxime in serious infections.

Authors:  P H Karakusis; J M Feczko; L J Goodman; D M Hanlon; A A Harris; S Levin; G M Trenholme
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

7.  Cefotaxime ("Claforan') in routine hospital use.

Authors:  K Connelly
Journal:  Curr Med Res Opin       Date:  1982       Impact factor: 2.580

8.  Enterococcal superinfection and colonization with aztreonam therapy.

Authors:  P H Chandrasekar; B R Smith; J L LeFrock; B Carr
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

9.  Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin.

Authors:  H C Neu; N X Chin; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

10.  Ceftazidime therapy of serious bacterial infections.

Authors:  L J Eron; R I Goldenberg; C H Park; D M Poretz
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

View more
  1 in total

1.  Respiratory tract colonization and incidence of secondary infection during hospital treatment of community-acquired pneumonia.

Authors:  A Ortqvist; S Hammers-Berggren; M Kalin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-10       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.